Improved therapeutic effect (higher CAR-T expansion and tumor rejection rate) coincided with increased global chromatin accessibility with a concomitant decrease in the accessibility of a subset of inhibitory receptors and effector transcription factors (including transcription factor 7 [TCF7] and lymphoid enhancer-binding factor 1 [LEF1]). Here, TCF7 is linked to neoplasm.